Last updated: November 7, 2026
VTAMA is the brand name for tapinarof cream, a nonsteroidal topical aryl hydrocarbon receptor agonist marketed for plaque psoriasis and atopic dermatitis. Its commercial value increased materially after the FDA expanded the label in 2024 to include adults and children aged 2 years and older with atopic dermatitis. The principal business issue is execution: VTAMA has a differentiated safety and usability profile, but it competes against low-cost generics, established specialty dermatology products and high-budget biologics.
What is VTAMA and who markets tapinarof?
VTAMA is a topical, nonsteroidal prescription medicine containing tapinarof 1% cream. Dermavant Sciences developed the product. Roivant Sciences was the parent company and commercial sponsor during the initial U.S. launch.
The FDA approved VTAMA in May 2022 for the topical treatment of plaque psoriasis in adults. In May 2024, FDA approved a supplemental application for topical treatment of mild, moderate and severe atopic dermatitis in adults and pediatric patients aged 2 years and older.[1,2]
In 2025, Organon agreed to acquire Dermavant and the VTAMA business from Roivant. The transaction repositioned VTAMA inside a global commercial infrastructure focused on women’s health, biosimilars and established specialty medicines. Organon’s involvement may improve sales-force reach, payer contracting and international expansion, although the economic value depends on the terms of the transaction and the company’s ability to fund dermatology commercialization.[3]
VTAMA is a drug brand, not a publicly traded company ticker. Financial results associated with the product have historically been reported through Roivant and Dermavant rather than through a standalone VTAMA public company.
What FDA approvals support the VTAMA market?
| FDA milestone |
Date |
Commercial effect |
| FDA approval for plaque psoriasis in adults |
May 24, 2022 |
Created the initial U.S. prescription market |
| U.S. commercial launch |
2022 |
Began specialty pharmacy and dermatology promotion |
| FDA approval for atopic dermatitis in adults and patients aged 2+ |
May 2024 |
Expanded the addressable population substantially |
| Organon agreement to acquire Dermavant and VTAMA |
2025 |
Shifted commercial ownership and operating responsibility |
The atopic dermatitis indication is commercially important because it expands VTAMA beyond adult psoriasis into a larger pediatric and primary-care-referred population. Atopic dermatitis also has greater treatment frequency in younger patients, where clinicians and caregivers often seek nonsteroidal alternatives to topical corticosteroids.
VTAMA’s label permits once-daily application. The product does not carry the corticosteroid-associated risks of skin atrophy and does not require steroid-class rotation. Those attributes support use on sensitive areas such as the face, folds and intertriginous regions, subject to the prescribing information and clinical judgment.[1,2]
How large is the addressable market for VTAMA?
VTAMA competes in two markets:
- Plaque psoriasis, where treatment ranges from generic topical corticosteroids and vitamin D analogs to oral therapies and biologics.
- Atopic dermatitis, where topical corticosteroids, topical calcineurin inhibitors, topical PDE4 inhibitors, topical JAK inhibitors and biologics are established treatment options.
The atopic dermatitis approval gives VTAMA access to a larger patient pool than the original psoriasis indication. The practical addressable market is narrower than total diagnosed prevalence because many patients respond adequately to inexpensive generic topical corticosteroids or do not seek prescription treatment.
Psoriasis market dynamics
In psoriasis, VTAMA’s key commercial advantages are:
- Nonsteroidal mechanism.
- Once-daily dosing.
- Use across body areas without steroid-related atrophy concerns.
- Potential use for patients who do not want systemic therapy.
- Potential maintenance use after disease control.
Its main disadvantages are:
- Higher cost than generic topical steroids.
- Competition from branded nonsteroidal topicals.
- Patient adherence challenges common to topical therapies.
- Limited suitability for patients requiring rapid control of extensive disease.
- Pressure from biologics and oral immunomodulators in moderate-to-severe disease.
Atopic dermatitis market dynamics
Atopic dermatitis offers stronger volume potential but a more crowded competitive environment. VTAMA competes with:
- Generic topical corticosteroids.
- Tacrolimus and pimecrolimus.
- Crisaborole.
- Ruxolitinib cream.
- Dupilumab and tralokinumab.
- Oral JAK inhibitors for selected patients.
- Other pipeline topical therapies.
The product’s best commercial segment is likely patients who need a nonsteroidal topical but are not ready for systemic treatment, or who have disease in sensitive locations where chronic corticosteroid exposure is a concern.
What is the financial trajectory for VTAMA?
VTAMA’s financial trajectory has three phases:
| Phase |
Business condition |
Financial implication |
| 2022 launch |
New product with one indication |
High selling and marketing expense relative to revenue |
| 2023 to early 2024 |
Prescription expansion in psoriasis |
Improving product revenue but continued commercialization costs |
| Post-2024 label expansion |
Access to atopic dermatitis and pediatric patients |
Higher sales potential and greater payer and physician reach |
| Post-Organon transaction |
New commercial owner |
Potentially lower standalone infrastructure costs and broader distribution |
Roivant’s public filings described VTAMA as a principal commercial product and reported growth in product revenue following the 2022 launch. The business remained dependent on continued prescription growth, formulary access and a favorable reimbursement environment rather than on a broad portfolio of approved products.[4]
The 2024 atopic dermatitis approval changed the financial profile. Before that approval, VTAMA relied heavily on the adult plaque psoriasis market. After approval, the product could be promoted for pediatric atopic dermatitis, increasing the potential number of treated patients and creating additional opportunities with dermatologists, pediatricians and primary-care prescribers.
The transaction with Organon also changes the cost structure. Dermavant’s standalone model required commercial, medical affairs, market access and corporate infrastructure. Integration into Organon could reduce duplicated costs and improve payer negotiations. The countervailing risk is that Organon may allocate resources toward products with higher near-term returns, limiting promotional intensity for VTAMA.
Publicly reported financial data do not establish VTAMA as a blockbuster product on the scale of major biologics. Its value is more likely to be measured through prescription growth, net price, refill persistence, gross-to-net discounts and the ability to secure preferred formulary treatment.
How does VTAMA compare with competing dermatology drugs?
| Product |
Active ingredient |
Main indications |
Strategic position |
| VTAMA |
Tapinarof |
Plaque psoriasis; atopic dermatitis |
Nonsteroidal topical with broad body-area utility |
| Eucrisa |
Crisaborole |
Atopic dermatitis |
Established nonsteroidal PDE4 inhibitor |
| Opzelura |
Ruxolitinib |
Atopic dermatitis; vitiligo |
Potent topical JAK inhibitor with boxed-warning considerations |
| Zoryve |
Roflumilast |
Plaque psoriasis; seborrheic dermatitis; atopic dermatitis |
Broadening topical PDE4 franchise |
| Tacrolimus ointment |
Tacrolimus |
Atopic dermatitis |
Generic nonsteroidal option |
| Topical corticosteroids |
Multiple |
Psoriasis; atopic dermatitis |
Low-cost first-line standard |
| Biologics |
Multiple |
Moderate-to-severe psoriasis or atopic dermatitis |
Systemic control for higher-severity disease |
VTAMA’s most direct commercial comparison is with Eucrisa, Zoryve and Opzelura. Generic tacrolimus and topical corticosteroids create the largest pricing pressure. Opzelura has stronger brand recognition and a broader immunomodulatory profile but carries important safety and labeling considerations. Zoryve has a competitive dosing and indication strategy that may pressure VTAMA in both psoriasis and atopic dermatitis.
VTAMA’s differentiation is strongest when physicians prioritize nonsteroidal treatment, once-daily dosing and broad application utility. Its differentiation is weaker when payers require generic step therapy or when patients have disease severity that justifies a biologic or oral therapy.
What patent and regulatory exclusivity protect VTAMA?
VTAMA is a small-molecule topical drug, not a biologic. Generic entrants would therefore use the abbreviated new drug application pathway rather than the biosimilar pathway.
The principal exclusivity layers are:
- FDA regulatory exclusivity associated with the new active ingredient approval.
- Orange Book-listed patents covering tapinarof, the formulation or approved methods of use.
- Potential pediatric exclusivity if FDA grants a qualifying six-month extension.
- Patent term adjustment or patent term extension, where applicable.
The 2022 approval likely provided new-chemical-entity regulatory exclusivity through 2027, subject to the applicable FDA designation and Orange Book record. Patent protection may extend beyond the regulatory exclusivity period. Exact generic-entry timing depends on the patents listed for the relevant product and the outcome of any Paragraph IV litigation.
What generic entry risks exist?
A generic company could challenge VTAMA through an ANDA containing a Paragraph IV certification. The main challenge areas would be:
- Composition of matter.
- Topical formulation and vehicle.
- Manufacturing process.
- Method of treating psoriasis.
- Method of treating atopic dermatitis.
- Patent validity, enforceability or infringement.
Topical products can present technical barriers because a generic must demonstrate pharmaceutical equivalence and satisfy FDA requirements relating to formulation, delivery and performance. Those barriers can delay entry but do not prevent a well-funded generic challenge.
The risk is higher after regulatory exclusivity expires because multiple generic manufacturers may have an incentive to target a branded topical with significant prescription volume. Patent litigation, a 30-month stay and settlement terms could materially change the entry date.
What is the Orange Book status of VTAMA?
FDA’s Orange Book is the controlling source for current patent listings, expiration dates and exclusivity status. VTAMA’s commercial risk should be analyzed using the current product-specific Orange Book entry rather than relying on launch-era patent summaries.
Relevant diligence points include:
| Issue |
Commercial relevance |
| Listed patents |
Defines the formal scope of ANDA certification risk |
| Patent expiration |
Establishes the earliest listed-patent barrier date |
| Pediatric exclusivity |
May extend protection by six months |
| Patent litigation |
Can impose a 30-month stay or alter launch timing |
| Settlement agreement |
May permit an agreed generic entry date |
| Formulation claims |
Can be more difficult to design around than method claims |
Because VTAMA is a topical small molecule, biosimilar competition is not relevant. The relevant threat is generic substitution through ANDA approval.
Are there Paragraph IV challenges or VTAMA settlements?
No definitive commercial forecast should assume generic launch before the end of listed patent and regulatory barriers. A Paragraph IV filing may become public through FDA or federal court records, but the filing itself does not establish that the generic will launch.
A material VTAMA settlement would normally address:
- The generic’s agreed launch date.
- Authorized-generic rights.
- Royalty or supply arrangements.
- Patent litigation dismissal.
- Pediatric exclusivity treatment.
- Restrictions on future formulations or indications.
The economic effect of a settlement would depend less on the mere existence of litigation than on whether the agreement permits entry years before the last enforceable patent expires.
What licensing and ownership changes affect VTAMA?
The ownership transition from Roivant and Dermavant to Organon is the most important recent strategic development. It changes the commercial sponsor, sales infrastructure and capital-allocation framework for VTAMA.[3]
The transaction could improve the product’s prospects through:
- Broader specialty-commercial coverage.
- Better payer contracting.
- Lower standalone operating costs.
- International commercialization capability.
- More efficient regulatory and medical-affairs support.
Risks include:
- Reduced investment if initial sales growth underperforms.
- Lower promotional spending after integration.
- Product deprioritization within a broader portfolio.
- Greater gross-to-net pressure from payer negotiations.
The transaction price and assumed obligations are important for valuation, but the product’s operating performance remains tied to net sales, prescription volume and contribution margin.
How strong is the VTAMA commercial position?
VTAMA has a credible product profile but not an unassailable market position.
Strengths
- Two FDA-approved dermatology indications.
- Pediatric atopic dermatitis label.
- Nonsteroidal profile.
- Once-daily topical administration.
- Potential use on sensitive body areas.
- Expansion into a large chronic inflammatory skin disease market.
- Strategic ownership by a global pharmaceutical company.
Weaknesses
- High competition from low-cost generics.
- Crowded branded topical market.
- Reimbursement step edits.
- Patient adherence problems with topical products.
- Limited systemic utility for extensive disease.
- Future ANDA and Paragraph IV risk.
- Dependence on continued promotional investment.
The patent estate is commercially useful only if the relevant claims withstand validity and enforceability challenges. Formulation and manufacturing claims may provide greater practical protection than narrow method-of-use claims, but the strength of each claim depends on the issued patent text and prosecution history.
What are the likely VTAMA launch scenarios?
| Scenario |
Market outcome |
Financial effect |
| Base case |
Moderate growth in psoriasis and atopic dermatitis |
Sustainable specialty-product revenue |
| Upside case |
Strong pediatric adoption, favorable formulary access and high refill rates |
Material revenue acceleration |
| Downside case |
Generic step therapy, weak persistence and competitive pressure from Zoryve or Opzelura |
Flat sales or declining net revenue |
| Generic-entry case |
ANDA approval after patent or settlement resolution |
Rapid price erosion and lower branded volume |
The best commercial outcome requires VTAMA to become a preferred nonsteroidal topical before patients escalate to systemic therapy. Pediatric adoption and use in sensitive areas are the most important growth levers. The major downside is that payers may treat VTAMA as a later-line branded topical despite its clinical differentiation.
Key Takeaways
- VTAMA is tapinarof 1% cream, a nonsteroidal topical approved for adult plaque psoriasis and atopic dermatitis in adults and children aged 2 years and older.
- The 2024 atopic dermatitis approval materially expanded the product’s addressable market.
- VTAMA competes against generic corticosteroids, tacrolimus, Eucrisa, Opzelura, Zoryve and systemic biologics.
- Its commercial advantages are once-daily dosing, nonsteroidal use and broad body-area utility.
- Its principal financial risks are payer restrictions, topical adherence, branded competition and future ANDA challenges.
- Organon’s acquisition of Dermavant changes the product’s commercial infrastructure and may improve distribution while creating integration and prioritization risk.
- VTAMA faces generic, not biosimilar, competition.
- Exact generic-entry timing depends on current Orange Book listings, regulatory exclusivity, patent litigation and any settlement agreement.
FAQs
Is VTAMA a biologic or a generic drug?
No. VTAMA is a branded small-molecule topical drug containing tapinarof. Future competitors would generally pursue an ANDA or another small-molecule regulatory pathway, not a biosimilar application.
Can children use VTAMA?
Yes. FDA expanded the label in 2024 to include patients aged 2 years and older with atopic dermatitis. The approved use and application instructions are defined in the prescribing information.[2]
Does VTAMA contain a steroid?
No. Tapinarof is a nonsteroidal aryl hydrocarbon receptor agonist.
What drugs are the closest commercial competitors to VTAMA?
The closest branded competitors include Eucrisa, Opzelura and Zoryve. Generic corticosteroids and tacrolimus are the largest price-based competitors.
What will determine the long-term value of VTAMA?
The key variables are pediatric atopic dermatitis adoption, formulary positioning, refill persistence, net pricing, Organon’s promotional investment and the timing of any generic entry.
References
-
U.S. Food and Drug Administration. (2022, May 24). FDA approves nonsteroidal topical treatment for plaque psoriasis. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024, May 24). FDA approves VTAMA (tapinarof) cream for atopic dermatitis. https://www.fda.gov/
-
Organon. (2025). Organon agreement to acquire Dermavant and VTAMA cream assets. Organon investor and corporate communications.
-
Roivant Sciences Ltd. (2024). Annual report and Form 10-K for the fiscal year ended March 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm